我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

巴曲酶防治冠心病PCI术后再狭窄的疗效(PDF)

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2005年第5期
页码:
458-460
栏目:
临床研究
出版日期:
2005-10-05

文章信息/Info

Title:
Preventive and curing effects of Batroxobin on post PCI restenosis
作者:
吕安林;  李丹;  贾国良 ; 陈丹 ; 苑媛
第四军医大学西京医院心血管内科，陕西 西安 710032
Author(s):
L Anlin; LI Dan;  JIA Guoliang; CHEN Dan; YUAN Yuan
Department of Cardiology,Xijing Hospital,Fourth Military Medical University,Xi′an,Shaanxi 710032,China
关键词:
巴曲酶; 经皮冠状动脉介入治疗; 再狭窄
Keywords:
batroxobin; percutaneous coronary intervention;  restenosis
分类号:
R541.4
DOI:
-
文献标识码:
A
摘要:
目的 观察巴曲酶防治经皮冠状动脉介入治疗（PCI）术后再狭窄的临床疗效。方法 100例PCI术后患者随机分成两组：Ａ组为常规低分子肝素抗凝治疗;B组在常规低分子肝素抗凝基础上，于术后第1、3、5天静滴巴曲酶15、10、10 BU。术后7 d观察纤维蛋白原（FIB)、PT、PLT、RBC的变化，术后6月观察两组的临床症状、心功能及超声心动图和实验室指标。结果 A组临床症状显效率60%，总有效率92%；B组临床症状显效率90%，总有效率98%。B组FIB显著降低，其它检查无明显变化，凝血酶原时间、活化的部分凝血酶原时间、血小板及红细胞等均无显著变化（P＞0.05）。A组左室射血分数（LVEF）由(50±6）%上升为（56±4）%，B组LVEF由(51±7）%上升为（61±5）%（P<0.01），B组PCI术后6月LVEF改善明显。在终点事件中，A组死亡2例，非致死性心肌梗死3例，难治性心绞痛5例；B组无上述事件发生。结论 巴曲酶对PCI术后再狭窄的防治具有显著的疗效，心功能的恢复显著，治疗中无出血等不良反应。
Abstract:
AIM To investigate the preventive and curing effect of Batroxobin on restenosis following percutaneous coronary intervention(PCI). METHODS The total of 100 patients post PCI were divided into group A and group B.Group A were treated regularly with low molecular weight heparin(LMWH). On the basis of LMWH therapy，group B were given batroxobin at 1 d(15 BU),3 d(10 BU) and 5 d(10 BU). The changes of FIB,PT,PLT,RBC were observed in the former three days. The clinical characteristics, heart function and changes of echocardioghraphy and laboratory indexes were observed.RESULTS The effective percentage of the clinical sign in group A was 60%,while the total effective percentage was 92%. The effective percentage of the clinical sign in group B was 90%,while the total effective percentage was 98%.At the same time,FIB in group B after treatment decreased dramatically.PT，APTT，PLT and RBC did not change significantly(P＞0.05). LVEF in group A were increased from (50±6）% up to（56±4）%，LVEF in group B from (51±7）% up to （61±5）%（P<0.01）. LVEF in group B recovered dramatically in 6 months after PCI. In the terminal events,there were two dead patients, three nonfatal infarction patients and five angina patients in group A;There were no events in group B. CONCLUSION Batroxobin remarkably prevents the development of post PCI restenosis .Heart functions are recovered dramatically.Moreover,there are no complications such as hemorrhages etc.

参考文献/References

［1］ Garza L,Ande YW,Saucedo JF.Can we prevent instent restenosis?［J］. Curr Opin Cardiol,2002,17(5):518-525.

［2］ Acevedo M,Pearce GL,Kottke LD,et al.Elevated fibrinogen and homocysteine levels enhance the risk of mortality in patients from a highrisk preventive cardiology clinic［J］. Arterioscler Thromb Vasc Bid,2002,22(6):1042-1045.

［3］ 张剑. 纤维蛋白原研究进展及其与再狭窄的关系［J］. 国外医学·心血管疾病分册, 2003,30（3）：145-147.

［4］ 刘新宏，何桂英，官功昌,等.巴曲抗栓酶治疗不稳定型心绞痛的疗效及其对血清肌钙蛋白I 水平的影响［J］. 心脏杂志,2001，13（2）：162-163.

［5］ Losordo DW,Lsner JW,Diaz-Sandoval LJ.Endothelial recovery:the next target in restenosis［J］. Circulation,2003 ,107(21):2635-2637.

［6］ Wang DS.Defibrinogenating effect of batroxin in vats and inhibition of migration of human vacular smooth muscle cells by the plasma of babroxobintreated rats in vitro［J］. Atherosclerosis,2001 ,156(1):73-80.

［7］ DeDios ST,Bruemmer D,Dilley RJ,et al.Inhibitory activity of clinical thiazolidinedione peroxisome proliferators actinating receptorgamma ligands toward internal mammary artery,radial artery,and saphenous vein smooth muscle cell proliferation［J］. Circulation,2003, 107(20):2548-2550.

［8］ Lounes KC,Lefkowitz JB,Coates AL,et al.Fibrinogen Longmout A heterozygous abnormal fibrinogen with B beta Arg166 to Cys substitution associated with defective fibrin polymerization［J］. Ann N Y Acad Sci,2001,936:129-132.

备注/Memo

备注/Memo:
收稿日期：2004-11-12.
更新日期/Last Update: 2010-01-05